The U.S. Food and Drug Administration (FDA) announced the target action date of its review of the sNDA for VTAMA (tapinarof) cream, 1% has changed.

Prior treatment use did not affect the efficacy or safety of topical ruxolitinib cream 1.5% for up to 52 weeks among patients with atopic dermatitis.

If not controlled with the above measures, your eczema might require prescription treatments like corticosteroids or even ...

Conventional treatment for eczema is based on the use of steroid creams which help to dampen the inflammation characteristic of this condition. However, these creams very rarely bring lasting ...

For 20% savings on some incredibly well-reviewed skincare products, you should absolutely check out the REN Evercalm sale at ...

The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

The harsh reality of winter isn’t just about bundling up—it’s about battling the season’s relentless assault on our hands.

THIS YEAR saw the 33rd European Academy of Dermatology and Venereology (EADV) Congress that, for the third time in its history, was ...

LEO Pharma has shared final results from a long-term extension study of its atopic dermatitis (AD) drug Adbry ...

Organon (OGN) stock on watch as FDA delays a potential label expansion for its VTAMA cream, impacting 2025 EBITDA margin and ...

The best treatment for you may depend on your specific diagnosis and the location of your eczema flare-up. Flare-ups are periods when the symptoms are worse, so take extra care of your skin during ...